LAUSR

1. Simon L, Fitsiori A, Lemal R, et al. Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French innovative Leukemia organization (FILO). Haematologica. 2015;100(12): 1587-1594. https://doi.org/10.3324/haematol.2015.133744. 2. Castillo JJ, D'Sa S, Lunn MP, et al. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016;172(5): 709-715. https://doi.org/10.1111/bjh.13883. 3. MinnemaMC, Kimby E, D'Sa S, et al. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica. 2017;102 (1):43-51. https://doi.org/10.3324/haematol.2016.147728. 4. Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(13):2227-2232. https:// doi.org/10.1200/JCO.2009.24.4905. 5. Kasenda B, Ihorst G, Schroers R, et al. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia. 2017;31(12):2623-2629. https://doi.org/10.1038/leu.2017.170. 6. DeFilipp Z, Li S, El-Jawahri A, et al. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer. 2017;123(16):3073-3079. https://doi.org/10.1002/cncr.30695. 7. Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16 (7):e322-e332. https://doi.org/10.1016/S1470-2045(15)00076-5. 8. Cabannes-Hamy A, Lemal R, Goldwirt L, et al. Efficacy of ibrutinib in the treatment of Bing–Neel syndrome. Am J Hematol. 2016;91(3): E17-E19. https://doi.org/10.1002/ajh.24279. 9. Mason C, Savona S, Rini JN, et al. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017;179(2):339-341. https://doi.org/10.1111/bjh.14218. 10. Castillo JJ, Itchaki G, Paludo J, et al. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019;133(4): 299-305. https://doi.org/10.1182/blood-2018-10-879593.